Wire · opportunities
Lecanemab's At-Home Start Dose Just Rewrote the Rules for Alzheimer's Trial Design
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 30 August 2026 · Fusion42 review
The FDA approved a subcutaneous starting dose of lecanemab that patients can self-administer at home, removing the need for initial infusion center visits and altering Alzheimer’s clinical trial designs and commercial treatment protocols.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 28 Aug 2026 and 30 Aug 2026.
◆ ◆ The Wire takeaway
You face a new regulatory landscape where starting Alzheimer’s treatment at home is standard. Adjust your trial protocols and patient recruitment strategy to remove infusion site dependencies and include caregiver training and remote safety monitoring.
◆ Coverage
2 sources · first reported 28 Aug 2026 · latest 30 Aug 2026
◆ Related on Wire
◆ Topics